Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Oncol ; 24(6): 1607-15, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15138606

RESUMO

Aclacinomycin (Aclarubicin) is a trisaccharide anthracycline anticancer drug active against a wide variety of solid tumors and haematological malignancies. We have evaluated its antimigrative and antiinvasive properties in a Boyden chamber with or without Matrigel and in wound repair assays. Aclacinomycin was demonstrated to inhibit HT-1080 cell migration and invasion while being more potent than the classical anthracycline doxorubicin. This decrease occurred in a dose-dependent manner and without affecting cell proliferation. Importantly, the antiinvasive effect was not associated to a modification in the production of the matrix-degrading enzymes MMP-2 and MMP-9 but rather to changes in cytoskeletal and focal contact formation. Indeed, the drug reduces cell polarity, impairs the actin-mediated membrane ruffling at the leading edge and decreases beta1 integrin expression and activation. Dramatic alterations in the distribution of vinculin and in the expression and phosphorylation state of both FAK and Src kinases were also detected. As a conclusion, these data suggest a novel application for this chemotherapeutic agent due to its ability to reduce tumor cell invasion. Combination of aclacinomycin with MMP inhibitors could have therapeutic potential in preventing tumor metastasis.


Assuntos
Aclarubicina/farmacologia , Antibióticos Antineoplásicos/farmacologia , Movimento Celular/efeitos dos fármacos , Fibrossarcoma/patologia , Invasividade Neoplásica/patologia , Proteína Tirosina Quinase CSK , Adesão Celular/efeitos dos fármacos , Meios de Cultivo Condicionados , Fibrossarcoma/enzimologia , Quinase 1 de Adesão Focal , Proteína-Tirosina Quinases de Adesão Focal , Humanos , Integrinas/metabolismo , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Proteínas Tirosina Quinases/metabolismo , Células Tumorais Cultivadas , Quinases da Família src
2.
Anal Cell Pathol ; 5(3): 135-46, 1993 May.
Artigo em Inglês | MEDLINE | ID: mdl-8343432

RESUMO

K562 human leukemia cell line undergoes in vitro terminal differentiation towards the erythroid pathway following treatments with appropriate chemical agents including aclacinomycin, fagaronine and hemin. These three drugs induced a different expression of phenotypic and functional characters associated with differentiation. The morphological characteristics of the differentiation sequences elicited by these agents were evaluated by image analysis using a SAMBA 200 cell image processor. Multivariate statistical analyses of morphological data revealed that only aclacinomycin was able to induce significant modifications of the morphological parameters similar to those observed during the maturation of normal bone-marrow erythroblastic cells. These data correlate with the higher inductive potency of aclacinomycin as compared to hemin or fagaronine and suggest that quantitative cytology may be a useful adjunct to conventional tests for the selection of new drugs with differentiating potential.


Assuntos
Aclarubicina/análogos & derivados , Alcaloides/farmacologia , Eritroblastos/patologia , Hemina/farmacologia , Leucemia/patologia , Fenantridinas , Aclarubicina/farmacologia , Benzofenantridinas , Diferenciação Celular/efeitos dos fármacos , Eritroblastos/efeitos dos fármacos , Hemoglobinas/biossíntese , Humanos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA